Blockchain Registration Transaction Record

TransCode Therapeutics Appoints Dr. Anna Moore, Inks Research Deal

TransCode Therapeutics appoints Dr. Anna Moore as Scientific Advisory Board Chair and signs research agreement with Michigan State University to advance RNA-based cancer therapy TTX-MC138.

This news matters because TransCode Therapeutics is advancing a novel RNA-based approach to treat metastatic cancer, which remains a leading cause of death worldwide. The appointment of Dr. Anna Moore and the research agreement with Michigan State University could accelerate the development of TTX-MC138, potentially offering new hope for patients with high-risk cancers that overexpress microRNA-10b. For investors, these developments signal strategic progress in the company's pipeline, which may influence future clinical outcomes and market positioning.